GET DAILY SIGNALSAirSculpt Technologies (AIRS): What to Watch in Q3 2026 Earnings
Key Takeaways
- AirSculpt Technologies (AIRS) is scheduled to report results for the third quarter of fiscal 2026 (the period ended September 30, 2026) in early November.
- Management has guided to a single-digit comparable revenue decline in Q3, excluding London center sales from the prior year, as softer consumer demand trends persisted into July.
- The company enters the quarter after two consecutive periods of stable revenue and positive same-center case growth, a meaningful turnaround from 2025's double-digit declines.
- Full-year 2026 revenue is expected at the lower end of the $151 million to $157 million range, while adjusted EBITDA guidance was narrowed to $12 million to $14 million.
- Investors will focus on case volume, average selling price, customer acquisition costs, and early traction in new procedures aimed at patients using GLP-1 weight-loss medications.
Earnings Context and Its Significance
AirSculpt Technologies, a national provider of premium, minimally invasive body contouring procedures, is navigating a turnaround in a challenging consumer spending environment. After same-center sales fell more than 20% in early 2025, the company has stabilized its revenue base and returned to positive case growth over the past two quarters. This upcoming report matters because it will test whether that stabilization can hold against choppy demand and rising marketing investment. For investors, Q3 results offer a read on the company's expanding procedure portfolio, its strategy to capture patients using GLP-1 weight-loss drugs, and its progress toward sustained profitable growth after an extended period of revenue declines and net losses. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
AirSculpt has not issued formal quarterly earnings-per-share guidance, but management offered directional commentary during its second-quarter call. On a comparable basis, excluding London center sales from 2025, the company expects third-quarter revenue to decline in the single digits year over year, followed by an anticipated return to growth in the fourth quarter as new service offerings and marketing efforts ramp.
For the full fiscal year 2026, management reaffirmed revenue at the lower end of its $151 million to $157 million range and lowered its adjusted EBITDA outlook to $12 million to $14 million, reflecting roughly $5 million in additional intentional marketing investment. By comparison, second-quarter revenue was $42.9 million (down 2.5% year over year), with adjusted EBITDA of $4.9 million and a net loss of $1.1 million. Key operating metrics to watch include case volume (which grew 1% year over year in Q2), average selling price (approximately $12,700), and customer acquisition cost, which rose to about $3,500 per case as the company ramped brand marketing.
Market Reaction and Investor Sentiment
Sentiment heading into the report is cautious but stabilizing. AirSculpt shares have benefited from the company's improving revenue trajectory and debt-reduction efforts, yet management's acknowledgment that sales trends softened in June and into July has tempered near-term expectations. The narrowed EBITDA guidance signals that margin pressure from marketing investment will persist in the near term, even as gross margins remain healthy at roughly 61% of revenue. Key risk factors include further weakening in discretionary consumer spending, elevated customer acquisition costs, and execution risk around newer procedures such as skin excision, mastopexy, and the recently announced AlloClae partnership. How the stock reacts will likely hinge on whether case volume momentum continues and whether management reaffirms its fourth-quarter growth expectations.
Forward Outlook and Key Factors to Monitor
Beyond the Q3 headline numbers, investors should track several forward-looking themes. The company's push to serve patients using GLP-1 weight-loss medications remains its most significant long-term opportunity. Management estimates nearly 19 million potential patients may be interested in body contouring or related aesthetic procedures, and its expanded service portfolio could represent more than $100 million in long-term revenue across the existing center base.
Marketing efficiency is a second critical factor. Customer acquisition cost has risen to roughly $3,500 per case, and management is refining its approach to GLP-1 patient outreach while adapting to changes in search-engine behavior. Whether that investment translates into higher conversion and case volume will shape profitability through 2026 and beyond.
Finally, balance-sheet discipline and liquidity remain in focus. The company reduced gross debt by more than $30 million since the start of 2025, extended its term loan maturity to November 2027, and ended Q2 with roughly $24 million in total liquidity. Guidance does not yet assume contributions from newer offerings or new center openings, leaving room for upside if execution improves—but also underscoring the near-term reliance on stabilizing the existing center base.
Exploring AI-Powered Research Tools
In my own analysis, I often turn to Tickeron’s AI Screener to quickly filter stocks by industry, technical patterns, and performance metrics. It helps surface relevant ideas and build watchlists ahead of earnings events like this one, allowing for more efficient comparisons across peers without manual effort.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AIRS's RSI Oscillator slumps oversold zone
The RSI Oscillator for AIRS moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +20.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where AIRS advanced for three days, in 235 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AIRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 55 cases where AIRS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AIRS as a result. In 67 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for AIRS turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AIRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AIRS entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.367) is normal, around the industry mean (204.220). P/E Ratio (-2.966) is within average values for comparable stocks, (21.249). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). AIRS's Dividend Yield (3.072) is considerably higher than the industry average of (0.154). P/S Ratio (0.921) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. AIRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AIRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement